www.smmttx.com Open in urlscan Pro
24.199.102.169  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Summit Therapeutics PLC
Summit Therapeutics PLC
 * Open submenu (Our Company)Our Company
 * Our Pipeline
 * Clinical Trials
 * Disease Information
 * Innovation Engine
 * Open submenu (Akeso Partnership)Akeso Partnership
 * Open submenu (News Center)News Center
 * Open submenu (Investor Center)Investor Center
 * Career Opportunities

Close submenu (Our Company)Our Company
 * Strategy & Mission
 * Leadership
 * Our Board
 * Partnering Opportunities
 * Out-Licensing Opportunities
 * Contact

Close submenu (Akeso Partnership)Akeso Partnership
 * Overview
 * Ivonescimab (SMT112) Overview
 * Therapeutic Areas

Close submenu (News Center)News Center
 * Media Resources
 * Press Releases

Close submenu (Investor Center)Investor Center
 * Investor Center
 * Announcements, Financial Reports & Filings
 * Email Alerts
 * Share Price Data
 * Analyst Coverage
 * Corporate Governance
 * Board of Directors Diversity Matrix
 * Shareholder Meetings
 * Summit Presentations

 * Our Company
   * Strategy & Mission
   * Leadership
   * Our Board
   * Partnering Opportunities
   * Out-Licensing Opportunities
   * Contact
 * Our Pipeline
 * Clinical Trials
 * Disease Information
 * Innovation Engine
 * Akeso Partnership
   * Overview
   * Ivonescimab (SMT112) Overview
   * Therapeutic Areas
 * News Center
   * Media Resources
   * Press Releases
 * Investor Center
   * Investor Center
   * Announcements, Financial Reports & Filings
   * Email Alerts
   * Share Price Data
   * Analyst Coverage
   * Corporate Governance
   * Board of Directors Diversity Matrix
   * Shareholder Meetings
   * Summit Presentations
 * Career Opportunities


COMMITTED TO OPTIMIZING
HUMAN HEALTH




Q4 & 2022 Earnings Call Partnership with Akeso


SUMMIT THERAPEUTICS

Summit is committed to leadership in resolving serious, unmet medical needs for
the betterment of overall HUMAN HEALTH.

Summit Therapeutics, Inc. has announced a definitive agreement of its
partnership with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”), to in-license its
breakthrough bispecific antibody, ivonescimab. Akeso is a pioneer and source
originator in developing innovative antibodies. The agreement supports Summit’s
mission of developing and commercializing groundbreaking oncology pipeline
products aimed at improving the quality of life of patients with serious unmet
medical needs. For Akeso, the deal represents an opportunity to introduce its
highly innovative antibodies to markets, including the United States, Canada,
Europe, and Japan – an important step towards Akeso’s strategic intention of
becoming a global biopharma organization.

Ivonescimab, known as AK112 in China and non-Summit territories, and also as
SMT112 in the United States, Canada, Europe, and Japan (Summit License
Territories), is a novel, potential first-in-class bispecific antibody combining
the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis
effects associated with blocking of VEGF into a single molecule. Ivonescimab is
the most advanced PD-1/VEGF bispecific antibody in clinical development in the
Summit License Territories: there are no known PD-1-based bispecific antibodies
approved by the U.S. Food and Drug Administration (“FDA”) or the European
Medicines Agency (“EMA”). Ivonescimab was engineered to bring two well
established oncology targeted mechanisms together.

Summit is initiating development activities for SMT112 and will do so first in
NSCLC indications. Summit plans to start treating patients in clinical studies
by the second quarter of 2023.

To learn more about this partnership: Akeso Partnership Overview

To learn more about ivonescimab (SMT112): Ivonescimab (SMT112) Fact Sheet

Download the Summit Therapeutics Corporate Overview Booklet: Corporate Overview
Booklet

 

IVONESCIMAB IS AN INVESTIGATIONAL THERAPY THAT IS NOT APPROVED ANY REGULATORY
AUTHORITY. IT IS CURRENTLY BEING INVESTIGATED IN PHASE III CLINICAL STUDIES.




LATEST NEWS


NEWS / 09 MAR 2023


SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS AND OPERATIONAL PROGRESS FOR THE
FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2022


NEWS / 03 MAR 2023


SUMMIT THERAPEUTICS CLOSES FULLY-SUBSCRIBED $500 MILLION RIGHTS OFFERING


NEWS / 23 FEB 2023


SUMMIT THERAPEUTICS’ RIGHTS OFFERING NEARING EXPIRATION DATE

View News Articles

> “THE PARTNERSHIP BETWEEN SUMMIT THERAPEUTICS AND AKESO IS A STRATEGICALLY
> COMPELLING OPPORTUNITY. IT REPRESENTS BRINGING TOGETHER AKESO’S EXTRAORDINARY
> TEAM, WHICH HAS BUILT AN INNOVATION ENGINE CAPABLE OF CREATING NOVEL
> BISPECIFIC TECHNOLOGIES, AND TEAM SUMMIT WITH ITS PROVEN TRACK RECORD OF
> SUCCESS OF GLOBAL CLINICAL DEVELOPMENT, REGULATORY APPROVALS, AND
> COMMERCIALIZATION, PARTICULARLY IN ONCOLOGY. WE BELIEVE THE POTENTIAL EXISTS
> FOR ENORMOUS CREATION THROUGH THIS PARTNERSHIP. WE ARE EXTREMELY ENCOURAGED BY
> IVONESCIMAB AND THE POTENTIAL FOR IMPROVING THE QUALITY AND DURATION OF
> PATIENTS’ LIVES BASED ON CLINICAL DATA TO SUPPORT THIS POINT. TEAM SUMMIT IS
> HONORED AND ENTHUSIASTIC TO PARTNER WITH AKESO. OUR SHARED MISSION AND VISION
> IS TO CREATE A SIGNIFICANT DIFFERENCE FOR THE BETTERMENT OF PATIENT HEALTHCARE
> OUTCOMES AROUND THE WORLD.”
> 
>  
> 
> Bob Duggan
> Chief Executive Officer & Chairman




> “AFTER REVIEWING A SUBSTANTIAL NUMBER OF OPPORTUNITIES, MUCH OF WHICH WAS
> FOCUSED ON POTENTIAL TREATMENTS FOR SOLID TUMORS, WE HAVE FOUND THE IDEAL
> PARTNERSHIP WITH THE POTENTIAL TO CHANGE THE PARADIGM FOR TREATING PATIENTS
> FACING DIFFICULT ODDS WITH DEVASTATING DIAGNOSES, TEN YEARS AGO, METASTATIC
> LUNG CANCER PATIENTS RARELY SURVIVED FOR MORE THAN TEN TO TWELVE MONTHS FROM
> DIAGNOSIS. TODAY, SURVIVAL CAN BE MEASURED IN YEARS. OUR GOAL IS TO IMPROVE
> THE QUALITY OF LIFE OF A PATIENT FACING IMMEASURABLE ODDS WHILE EXTENDING THE
> DURATION OF THAT PATIENT’S LIFE. OUR FOCUS IS ALWAYS ON HOW WE CAN IMPROVE THE
> LIVES OF PATIENTS. WE SOUGHT PATIENT-FRIENDLY MEDICINAL THERAPIES THROUGH OUR
> SEARCH TO EXPAND OUR PIPELINE PORTFOLIO, AND WE ARE PROUD TO TAKE THIS
> MEANINGFUL STEP TOWARDS ACCOMPLISHING THIS GOAL. WE HAVE SIGNIFICANT WORK TO
> DO, BUT WE ARE STEADFASTLY COMMITTED TO BRINGING IVONESCIMAB INTO THE HANDS OF
> PATIENTS WHO NEED IT MOST. WE ARE THRILLED TO REACH THIS AGREEMENT WITH
> MICHELLE AND THE TEAM AT AKESO, AND WE ARE EXCITED TO MAKE THIS VISION A
> REALITY. I AM PROUD OF TEAM SUMMIT WHO HAVE DILIGENTLY WORKED THESE PAST FEW
> MONTHS TO ESTABLISH A STRONG BOND WITH THE TEAM AT AKESO, AND I WOULD LIKE TO
> THANK AKESO FOR SPENDING SO MUCH TIME CREATING THIS MEANINGFUL PARTNERSHIP.”
> 
>  
> 
> Maky Zanganeh
> Co-Chief Executive Officer & President



 * ABOUT SUMMIT THERAPEUTICS
 * Akeso Partnership
 * Ivonescimab (SMT112) Overview
 * Our Pipeline
 * Media Resources

 * Investor Center
 * Press Releases
 * Reports & Filings
 * Share Price Data
 * Contact

 * Social Media Platforms
 * Twitter
 * Linkedin

© 2023 Summit Therapeutics Inc.

Trademarks, registered or otherwise, are the property of their respective
owner(s). Website Designed and Developed by Carr Kamasa Design

 * Disclaimer
 * Privacy Policy
 * Online Terms of Use
 * Site Map


WEBSITE COOKIES

This website uses cookies: Please see our Privacy Policy to understand how we
use cookies. Okay, thanks